Page 8 - Xlife Sciences News Today

Track breaking Austria Coronavirus headlines on NewsNow: the one-stop shop for Austria Coronavirus news

Investegate announcements from Xlife Sciences AG, Successful license deal with Vitese Trading GmbH

Inflamed pharma GmbH signs license agreement with Vitesse Trading GmbHZURICH, SWITZERLAND / ACCESSWIRE / October 7, 2021 / The Xlife-project company inflamed pharma GmbH has concluded an exclusive license

Search jobs VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development HEIDELBERG, Germany and ZUG, Switzerland, June 14, 2021 / B3C newswire / --VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), a leading company in innovative ADC engineering and functional antibody screening, announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of...

First available holistic medical drug to treat Covid-19 and flu viruses ZUERICH, SWITZERLAND / ACCESSWIRE / June 10, 2021 / As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has

Investegate announcements from Xlife Sciences AG, Breakthrough in Drug Development

First available holistic medical drug to treat Covid-19 and flu viruses ZURICH, SWITZERLAND - EQS Newswire - 10 June 2021 - As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active substance ProcCluster (R) reduces the viral load by...

DGAP-News: Xlife Sciences AG: Portfolio project listed on the Stock Exchange Xlife Sciences AG: Portfolio project listed on the Stock Exchange 14.05.2021 / 15:41 PRESS RELEASE Vitruvia Medical AG is listed on the Munich Stock Exchange since yesterday The shares of Vitruvia Medical AG are open for trading since yesterday on the Stock exchange in Munich. Vitruvia is based in Germany and Switzerland and develops circulatory systems for highly complex medical devices as a project portfolio of Xl...

Operator Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and Ill be your operator for todays call. [Operator Instructions] I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin. Steven Rubis -- Investor Relations Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenexs business as well as a review of financial results for the first quarter of 2021. The news rel...

DGAP-News: Xlife Sciences AG / Key word(s): Merger 05.03.2021 / 07:30 Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies Development of highly effective antibodies without animal testing Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue fo...